Novo infuses cash into 4 biotechs, adding to their arsenal for the superbugs battle to come
A year after Novo Holdings launched a $165 million fund to fill what it sees as an early-stage funding gap in research addressing the growing threat of antimicrobial resistance, it’s offering a review of four investments Novo has made totaling $20 million.
AstraZeneca-backed Entasis Therapeutics, Lund University spinout Minervax and UK-based Procarta Biosystems were selected alongside Polyphor, a Swiss biotech that previously announced Novo’s backing of its outer membrane protein targeting antibiotics (OMPTA) programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.